» Articles » PMID: 37563849

A Global Survey of Health Care Workers' Awareness of Non-alcoholic Fatty Liver Disease: The AwareNASH Survey

Abstract

Background: The estimated global prevalence and burden of non-alcoholic fatty liver disease (NAFLD) and its advanced stage, non-alcoholic steatohepatitis (NASH), is increasing. Yet, NAFLD remains largely underdiagnosed. In addition to hepatic morbidity and mortality, NAFLD is associated with increased cardiovascular complications, warranting a multidisciplinary approach. Despite its rapidly increasing prevalence, knowledge of NAFLD among healthcare workers is limited, especially with specialists outside the field of hepatology and gastroenterology.

Objectives: To investigate knowledge, practice and opinions/attitudes of healthcare workers towards diagnosis and management of NAFLD/NASH.

Methods: The survey was designed in collaboration with a multidisciplinary scientific committee established especially for this study. The survey was disseminated to healthcare workers from seven different disciplines through four collaborating societies, social media and at a cardiology-themed conference from February to June 2022. Median and interquartile range were mentioned for numeric responses and proportions for categorical responses or responses on a Likert scale. Likert scale responses were treated as ordinal data and analysed with the appropriate tests.

Results: The full dataset included 613 respondents from 88 different countries (including 488 physicians). 64% of the surveyed physicians underestimated the prevalence of NAFLD. General practitioners and cardiologists underestimated the prevalence most often (74% and 77%, respectively). Compared to the other disciplines, cardiologists were least familiar with the symptoms and diagnostic criteria and felt least confident in diagnosing and managing NAFLD. Overall, 65% of physicians reported regularly using evidence-based guidelines for managing NAFLD, yet 72% reported challenges in providing lifestyle recommendations. A lack of awareness was the most common reported reason for the lack of screening for NAFLD (68% respectively).

Conclusions: Despite the growing burden of NAFLD, there is a significant gap in awareness, knowledge, and management among physicians treating patients with cardiometabolic comorbidities, particularly cardiologists. Hepatologists and gastroenterologists could play a role in educating their fellow physicians.

Citing Articles

The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease.

Heymann C, Mak A, Holleboom A, Verheij J, Shiri-Sverdlov R, van Mil S Lipids Health Dis. 2024; 23(1):402.

PMID: 39696394 PMC: 11653580. DOI: 10.1186/s12944-024-02380-x.


A Survey Assessing Nonalcoholic Fatty Liver Disease Knowledge Among Hepatologists and Non-Hepatologists in China.

Colombo L JGH Open. 2024; 8(12):e70054.

PMID: 39659486 PMC: 11629256. DOI: 10.1002/jgh3.70054.


A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol.

Fishman J, Alexander T, Kim Y, Kindt I, Mendez P J Comp Eff Res. 2024; 13(10):e240085.

PMID: 39301878 PMC: 11426282. DOI: 10.57264/cer-2024-0085.


Metabolic Dysfunction-Associated Fatty Liver Disease and Fibrosis Status in Patients with Type 2 Diabetes Treated at Internal Medicine Clinics: Türkiye DAHUDER Awareness of Fatty Liver Disease (TR-DAFLD) Study.

Sahinturk Y, Koker G, Koca N, Sumbul H, Demir I, Keskin H Turk J Gastroenterol. 2024; 35(8):643-650.

PMID: 39150440 PMC: 11363181. DOI: 10.5152/tjg.2024.24045.


Barriers to care linkage and educational impact on unnecessary MASLD referrals.

Lee J, Laurel Yoon E, Oh J, Kim K, Ahn S, Won Jun D Front Med (Lausanne). 2024; 11:1407389.

PMID: 39118663 PMC: 11309125. DOI: 10.3389/fmed.2024.1407389.


References
1.
Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S . Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014; 61(5):1547-54. DOI: 10.1002/hep.27368. View

2.
Loomba R, Friedman S, Shulman G . Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021; 184(10):2537-2564. DOI: 10.1016/j.cell.2021.04.015. View

3.
Duell P, Welty F, Miller M, Chait A, Hammond G, Ahmad Z . Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2022; 42(6):e168-e185. DOI: 10.1161/ATV.0000000000000153. View

4.
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L . Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology. 2015; 149(2):367-78.e5. DOI: 10.1053/j.gastro.2015.04.005. View

5.
Younossi Z, Golabi P, de Avila L, Paik J, Srishord M, Fukui N . The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019; 71(4):793-801. DOI: 10.1016/j.jhep.2019.06.021. View